Winners And Losers: A Deep-Dive Into The EMA’s PRIME Scheme

Nine of the 70 medicines for unmet medical needs that have to date won a place on the European Medicines Agency’s PRIME scheme are now approved for sale in the EU, and two more approvals are expected soon. Meanwhile, most applications for a "priority medicine" designation are still missing the mark.

Research scientist
PRIME is designed to help drug developers generate robust data • Source: Shutterstock

Drug developers are continuing to show a lot of interest in the European Medicines Agency’s priority medicines (PRIME) scheme and the advantages it offers.

Since the scheme was launched in 2016, the EMA has received over 300 applications from companies seeking a PRIME designation...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from R&D

More from Pink Sheet